glp 1 antagonist exendin The DPP-4 inhibitor linagliptin and the GLP-1 receptor agonist exendin-4 improve endothelium-dependent relaxation of rat mesenteric arteries in the presence of high glucose ExendinFragment 9 Probing the N-terminal structure of

The choice depends on medical eligibility, insurance coverage, and availability

The hospitals segment held the largest share of the GLP-1 targeted peptide weight loss drugs market in 2024, owing to their comprehensive healthcare infrastructure and ability to manage complex obesity cases requiring close monitoring

Pivoting back to the obesity space, a year-long Phase 2 study comparing semaglutide daily to 0.6 mg of liraglutide daily and placebo demonstrated the superiority of semaglutide over liraglutide in all doses above 0.2 mg (NCT02453711)

Any future GLP-1 patch formulations would need to demonstrate similar therapeutic benefits across these indications through rigorous clinical trials before receiving regulatory approval from the MHRA and EMA